Patient recruitment

New Centre for Medicines Research (CMR) Clinical Factbook From Clarivate Highlights Increasing Cost and Complexity of Phase II Trials

Retrieved on: 
Tuesday, November 24, 2020
Health sciences, Pharmaceutical industry, Health, Clinical research, Life sciences, Drug discovery, Design of experiments, Clinical trial, Patient recruitment, Phases of clinical research

The factbook reveals clinical trial volume has increased by 7% between 2014 and 2019 with Phase II trials accounting for the majority of trials initiated during the period.

Key Points: 
  • The factbook reveals clinical trial volume has increased by 7% between 2014 and 2019 with Phase II trials accounting for the majority of trials initiated during the period.
  • The annual publication provides insights on clinical study, country and site level metrics from Phase I through Phase IV.
  • Leading pharmaceutical and biotechnology companies can assess clinical productivity and leverage industry trends and insights to make informed clinical planning decisions.
  • The 2020 CMR International Pharmaceutical Clinical Factbook indicates, while Phase I and II clinical trials tend to be the most complex, Phase III trials have also seen an increase in complexity.

New Centre for Medicines Research (CMR) Clinical Factbook From Clarivate Highlights Increasing Cost and Complexity of Phase II Trials

Retrieved on: 
Tuesday, November 24, 2020
Health sciences, Pharmaceutical industry, Health, Clinical research, Life sciences, Drug discovery, Design of experiments, Clinical trial, Patient recruitment, Phases of clinical research

The factbook reveals clinical trial volume has increased by 7% between 2014 and 2019 with Phase II trials accounting for the majority of trials initiated during the period.

Key Points: 
  • The factbook reveals clinical trial volume has increased by 7% between 2014 and 2019 with Phase II trials accounting for the majority of trials initiated during the period.
  • The annual publication provides insights on clinical study, country and site level metrics from Phase I through Phase IV.
  • Leading pharmaceutical and biotechnology companies can assess clinical productivity and leverage industry trends and insights to make informed clinical planning decisions.
  • The 2020 CMR International Pharmaceutical Clinical Factbook indicates, while Phase I and II clinical trials tend to be the most complex, Phase III trials have also seen an increase in complexity.

Healint Starts Third Virtual Clinical Trial Amid COVID-19 Pandemic

Retrieved on: 
Wednesday, November 18, 2020
Clinical research, Health sciences, Pharmaceutical industry, Health, Medical research, Clinical trials, Design of experiments, Migraine, Patient recruitment, Electronic patient-reported outcome

NEW YORK, Nov. 18, 2020 /PRNewswire/ -- Healint , a leading provider of healthcare technology and developer of the Migraine Buddy tracking app, is now recruiting patients for its third virtual global clinical trial in the past two years.

Key Points: 
  • NEW YORK, Nov. 18, 2020 /PRNewswire/ -- Healint , a leading provider of healthcare technology and developer of the Migraine Buddy tracking app, is now recruiting patients for its third virtual global clinical trial in the past two years.
  • With COVID-19 reducing the ability of patients to visit medical facilities and clinical trial sites in person and after the successful completion of its first two virtual trials with the world's largest research-based pharmaceutical leaders, Healint is utilizing its industry leading virtual clinical trial capabilities to recruit patients to participate in a new trial for ePRO measures for an acute migraine medication.
  • Moving clinical trials to a virtual setting also eliminates the need for in-person patient or nurse visits, cumbersome paper records, and armies of clinical research associates to monitor the accuracy of patient data.
  • Recruitment for Healint's third virtual trial will conclude by the third quarter of 2021, and the trial is expected to last for eight to twelve months.

StudyKIK Announces Patient Recruitment, Telemedicine, eConsent, & ePro Mobile Retention Applications Under a Single, Site-Focused Technology Platform

Retrieved on: 
Thursday, November 12, 2020
Health sciences, Pharmaceutical industry, Articles, Health, Clinical trials, Clinical research, Advertising, Patient recruitment, Recruitment, EPRO, Telehealth

IRVINE, Calif., Nov. 12, 2020 /PRNewswire-PRWeb/ -- StudyKIK, a clinical trial patient recruitment and retention technology company that is focused on decreasing enrollment timelines, announced today the interconnectivity of their complete technology platform.

Key Points: 
  • IRVINE, Calif., Nov. 12, 2020 /PRNewswire-PRWeb/ -- StudyKIK, a clinical trial patient recruitment and retention technology company that is focused on decreasing enrollment timelines, announced today the interconnectivity of their complete technology platform.
  • This platform includes a complete patient recruitment management interface that is connected with eConsent, telemedicine, and ePro mobile patient retention applications.
  • StudyKIK provides recruitment and retention technology solutions for patients, sites, CROs, and sponsors as well as customized app technology to assist with patient retention once patients are randomized.
  • As a result, StudyKIK is the global leader in patient recruitment and retention strategy and implementation.

Arch Biopartners Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19

Retrieved on: 
Thursday, November 5, 2020
Pharmaceutical industry, Clinical trials, Health sciences, Health, Medical research, Advertising, Patient recruitment, Recruitment, Clinical research

The first patient was dosed in Istanbul yesterday and patient recruitment at the Istanbul site is now ongoing.

Key Points: 
  • The first patient was dosed in Istanbul yesterday and patient recruitment at the Istanbul site is now ongoing.
  • Additional patients are expected to be enrolled this week at a second clinical site in Ankara, the nations capital.
  • The Phase II results will be used to design the Phase III trial, including greater patient numbers to more fully evaluate efficacy and safety in COVID patients.
  • For more information on Arch Biopartners, its technologies and other public documents Arch has filed on SEDAR, please visit www.archbiopartners.com
    The Company has 60,782,302 common shares outstanding.

Rexgenero Announces Positive Outcome of Independent Data Monitoring Committee Meeting for Phase III Trial for Diabetic Patients with Critical Limb-Threatening Ischaemia

Retrieved on: 
Monday, October 26, 2020
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical trials, Clinical research, Health sciences, Medical research, Health, Pharmaceutical industry, Design of experiments, Clinical trials, Drug discovery, Placebo-controlled study, Patient recruitment, Placebo, Rexgenero, REX-001 and the Phase III SALAMANDER clinical trials

Rexgenero, a regenerative medicine company developing advanced cell therapies to treat critical limb-threatening ischaemia (CLI), today announces that the Independent Data Monitoring Committee (IDMC) for its REX-001 phase III clinical trial recently met to review patient safety and tolerability data from the initial 22 subjects.

Key Points: 
  • Rexgenero, a regenerative medicine company developing advanced cell therapies to treat critical limb-threatening ischaemia (CLI), today announces that the Independent Data Monitoring Committee (IDMC) for its REX-001 phase III clinical trial recently met to review patient safety and tolerability data from the initial 22 subjects.
  • We are pleased to receive the IDMCs recommendation that our REX-001 phase III clinical study should continue without any protocol modifications.
  • Despite the unprecedented challenges of the COVID-19 pandemic, we believe we are back on track in terms of patient recruitment and moving the REX-001 phase III trial forward.
  • The phase III study is a pivotal, placebo-controlled, double-blind, parallel-group, adaptive trial conducted in subjects with diabetes and Rutherford Category 5 CLI.

CISCRP Honors "Medical Heroes," Participants in Clinical Trials

Retrieved on: 
Friday, October 23, 2020
Health sciences, Health, Clinical research, Medical research, Clinical trials, Pharmaceutical industry, Design of experiments, Parkinson's disease clinical research, Patient recruitment

Study participants and researchers focused on clinical research experiences and misconceptions, health advocacy and equity, and how the pandemic has impacted clinical trials.

Key Points: 
  • Study participants and researchers focused on clinical research experiences and misconceptions, health advocacy and equity, and how the pandemic has impacted clinical trials.
  • Anyone interested in learning more about participating in clinical trials can obtain information from CISCRP at 1-877-MED-HERO or http://www.ciscrp.org .
  • CISCRP offers a free service designed to help patients and caregivers find clinical trials within their medical condition and location at http://www.searchclinicaltrials.org .
  • The Center for Information and Study on Clinical Research Participation (CISCRP) is a 501(c)(3) non-profit organization dedicated to engaging the public and patients as partners in the clinical research process.

First Patient Dosed in Phase II Trial to Treat Complications in COVID-19

Retrieved on: 
Friday, October 16, 2020
Health, Pharmaceutical industry, Clinical trials, Articles, Advertising, Patient recruitment, Recruitment, Drugs, Coronavirus disease

The first patient dosed was at the Broward Health Medical Center in Florida where patient recruitment into the trial continues.

Key Points: 
  • The first patient dosed was at the Broward Health Medical Center in Florida where patient recruitment into the trial continues.
  • Arch will begin screening and recruiting patients next week at clinical sites in Louisiana and in Turkey.
  • The composite primary endpoint of the phase II trial reflects the severe effects often experienced by hospitalized COVID-19 patients and deemed appropriate for LSALT peptides novel mechanism of action in blocking consequential inflammation in the lungs and kidneys.
  • The Phase II results will be used to design the Phase III trial, including greater patient numbers to more fully evaluate efficacy and safety in COVID patients.

BetterLife Announces VirTrial as Clinical Trial Patient Monitoring Partner

Retrieved on: 
Thursday, October 8, 2020
Articles, Health, Clinical research, Pharmaceutical industry, Clinical trials, Advertising, Patient recruitment, Recruitment, Telehealth, Research site, Clinical trial portal

VirTrial is a telehealth platform provider that is changing the way pharmaceutical companies conduct clinical trials and enabling research sites to improve patient recruitment and retention.

Key Points: 
  • VirTrial is a telehealth platform provider that is changing the way pharmaceutical companies conduct clinical trials and enabling research sites to improve patient recruitment and retention.
  • Incorporating virtual visits facilitates BetterLife to evaluate, qualify and routinely monitor both patients and research sites for studies without physical travel.
  • Unlike other clinical trial vendors that began as technology companies, VirTrial has a stable team of clinical research veterans and experienced tech entrepreneurs teaming together to lead the company towards providing the human population with remote access to clinical research sites.
  • VirTrial is a bioscience technology company providing a stable, long-standing telemedicine platform to transform the clinical trial industry.

Trialbee Patient Recruitment Services Selected to Promote Patient Diversity for Leading COVID-19 Vaccine Trials

Retrieved on: 
Tuesday, October 6, 2020
Health, Other Consumer, Consumer, Women, Clinical trials, MEN, Pharmaceutical, Health, Clinical trials, Clinical research, Drug discovery, Patient recruitment, Recruitment, Biomedical Advanced Research and Development Authority, Vaccine, Pharmaceutical industry, Operation Warp Speed, COVID-19 vaccine

Trialbee, a leading global technology provider for patient matching and engagement in clinical trials, today announced that the company is providing patient recruitment services to promote patient diversity for vaccine trials funded by the Biomedical Advanced Research and Development Authority (BARDA) , part of the HHS Office of the Assistant Secretary for Preparedness and Response .

Key Points: 
  • Trialbee, a leading global technology provider for patient matching and engagement in clinical trials, today announced that the company is providing patient recruitment services to promote patient diversity for vaccine trials funded by the Biomedical Advanced Research and Development Authority (BARDA) , part of the HHS Office of the Assistant Secretary for Preparedness and Response .
  • The clinical trials, sponsored by global pharmaceutical companies, are investigating the safety and efficacy of leading vaccine candidates against the novel coronavirus (COVID-19).
  • Our recent engagements reflect how Trialbee is helping research communities to accelerate and predictably deliver high-quality recruitment for ongoing vaccine trials.
  • Trialbee is a world leading technology provider in patient matching and engagement, empowering patients to participate in clinical trials as a care option.